The Quest for Affordable Monoclonal Antibodies and Targeted Therapy in Lung Cancer
Main Article Content
Abstract
Costs of anticancer drugs are generally and rightly labeled expensive. Many nations across the globe have limited resources and could hardly afford the basic necessary medications. The United States (US) government in 2022 allocated17.3% of the gross domestic product (GDP) on health care. A $28,176.6 trillion dollars was spent in 2024 on health care, with a significant portion covering drug costs. Insulin price was reduced to $35 with plans to limit other medications costs.
Article Details
How to Cite
GUIRGIS, Helmy M..
The Quest for Affordable Monoclonal Antibodies and Targeted Therapy in Lung Cancer.
Medical Research Archives, [S.l.], v. 12, n. 8, aug. 2024.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/5689>. Date accessed: 06 sep. 2024.
doi: https://doi.org/10.18103/mra.v12i8.5689.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: A framework to assess the value of cancer treatment options. J Clin Oncol. June 22, 2015.
2. Cherny NI, Sullivan R, Dafni U, et al. A standardized, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies. The European Society for Medical Oncology: magnitude of clinical benefit scale (ESM-MCBS): Oxford University Press; 2015.
3. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med. 372:2018–28, 2015.
4. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:823–1833, 2016.
5. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-postive, advanced non-small-cell lung cancer (KEYNOTE -010): A randomised controlled trial. Lancet 387: 1540-1550, 2016.
6. Guirgis. HM. Costs of Target Therapy and Proportionality to Number of Purchases: Propose Using Maintenance Dose and Limited Duration. ESMED 2024. Doi https://doi.org/10.18103/mra.v 12i1.4959.ISSN:2375-1924.
7. Herbst RS, Wu Yi-long, John T, Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results from the Phase III Randomized ADAURA Trial, J Clin Oncol, 2023 Jan 31; JCO2202186. doi: 10.1200/JCO.22.02186.
8. Lv C, Fang W, Wu N, et al. Osimertinib as Neoadjuvant Therapy for EGFR-Mutant Resectable Stage II-IIIB Lung Adenocarcinoma. Lung Cancer; 2023 Feb 17; 178,151-156.
9. Li M, Liao K, Pan I-Wen et al. Growing Financial burden from high cost targeted oral anticancer medicines among Medicare beneficiaries with cancer. JCO oncology practice ,18,11,759, 2002.
10. Peppercorn, J. The impact of financial toxicity on cancer care. Clin adv, Hem & Onc. 21, October 2023.
11. Guirgis, HM. Costs of extended immune check point inhibitors treatment in advanced/metastatic lung cancer: Bundling of cost proposal. ASCO May-June 2020 annual meeting, Chicago, abstract 291815.
12. Kline RK. Bundled Payment Models in Oncology: Learning to Think in New Ways DOI: 10.1200/OP.20.00735JCO Oncology Practice, Published online February 04, 2021, PMID:33539197.
13. Ragavan MV, Swartz S, Clark M, et al. Access to financial assistance programs and their impact on overall spending on oral anticancer medications at an integrated specialty pharmacy. Ascopubs.org/journal/op, 20 February 2024.
14. Del Paggio JC, Naipaul R, Gavura S, et al. Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study. www.thelancet.com/oncology, vol 25, April 2024.
15. The lancet Oncology. Editorial. Safe and effective cancer care: how long must we wait? 25, March 2024.10.1007/s13555-021-00596-8.
16. Guirgis, HM. Reducing the Financial Toxicity of Prolonged Therapy in advanced/Metastatic Lung Cancer, Saving Methodology
17. Guirgis, H, Cost matters. journal of Cancer & Oncology (OAJCO) Commentary Volume 7 Issue 1, April 19, 2023. DOI: 10.23880/oajco-16000184.
2. Cherny NI, Sullivan R, Dafni U, et al. A standardized, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies. The European Society for Medical Oncology: magnitude of clinical benefit scale (ESM-MCBS): Oxford University Press; 2015.
3. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med. 372:2018–28, 2015.
4. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:823–1833, 2016.
5. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-postive, advanced non-small-cell lung cancer (KEYNOTE -010): A randomised controlled trial. Lancet 387: 1540-1550, 2016.
6. Guirgis. HM. Costs of Target Therapy and Proportionality to Number of Purchases: Propose Using Maintenance Dose and Limited Duration. ESMED 2024. Doi https://doi.org/10.18103/mra.v 12i1.4959.ISSN:2375-1924.
7. Herbst RS, Wu Yi-long, John T, Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results from the Phase III Randomized ADAURA Trial, J Clin Oncol, 2023 Jan 31; JCO2202186. doi: 10.1200/JCO.22.02186.
8. Lv C, Fang W, Wu N, et al. Osimertinib as Neoadjuvant Therapy for EGFR-Mutant Resectable Stage II-IIIB Lung Adenocarcinoma. Lung Cancer; 2023 Feb 17; 178,151-156.
9. Li M, Liao K, Pan I-Wen et al. Growing Financial burden from high cost targeted oral anticancer medicines among Medicare beneficiaries with cancer. JCO oncology practice ,18,11,759, 2002.
10. Peppercorn, J. The impact of financial toxicity on cancer care. Clin adv, Hem & Onc. 21, October 2023.
11. Guirgis, HM. Costs of extended immune check point inhibitors treatment in advanced/metastatic lung cancer: Bundling of cost proposal. ASCO May-June 2020 annual meeting, Chicago, abstract 291815.
12. Kline RK. Bundled Payment Models in Oncology: Learning to Think in New Ways DOI: 10.1200/OP.20.00735JCO Oncology Practice, Published online February 04, 2021, PMID:33539197.
13. Ragavan MV, Swartz S, Clark M, et al. Access to financial assistance programs and their impact on overall spending on oral anticancer medications at an integrated specialty pharmacy. Ascopubs.org/journal/op, 20 February 2024.
14. Del Paggio JC, Naipaul R, Gavura S, et al. Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study. www.thelancet.com/oncology, vol 25, April 2024.
15. The lancet Oncology. Editorial. Safe and effective cancer care: how long must we wait? 25, March 2024.10.1007/s13555-021-00596-8.
16. Guirgis, HM. Reducing the Financial Toxicity of Prolonged Therapy in advanced/Metastatic Lung Cancer, Saving Methodology
17. Guirgis, H, Cost matters. journal of Cancer & Oncology (OAJCO) Commentary Volume 7 Issue 1, April 19, 2023. DOI: 10.23880/oajco-16000184.